NASDAQ:ACAD ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis $16.07 -0.15 (-0.92%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$15.76▼$16.4650-Day Range$15.14▼$19.1452-Week Range$14.55▼$32.59Volume857,217 shsAverage Volume1.78 million shsMarket Capitalization$2.66 billionP/E RatioN/ADividend YieldN/APrice Target$25.56 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ACADIA Pharmaceuticals alerts: Email Address ACADIA Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.69 Rating ScoreUpside/Downside59.1% Upside$25.56 Price TargetShort InterestHealthy6.45% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.81Based on 7 Articles This WeekInsider TradingSelling Shares$793,914 Sold Last QuarterProj. Earnings Growth63.46%From $0.52 to $0.85 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.58 out of 5 starsMedical Sector77th out of 910 stocksPharmaceutical Preparations Industry29th out of 426 stocks 4.3 Analyst's Opinion Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 11 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ACADIA Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.45% of the outstanding shares of ACADIA Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently decreased by 7.38%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACAD. Previous Next 2.1 News and Social Media Coverage News SentimentACADIA Pharmaceuticals has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for ACADIA Pharmaceuticals this week, compared to 7 articles on an average week.Search InterestOnly 9 people have searched for ACAD on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $793,914.00 in company stock.Percentage Held by Insiders28.30% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ACADIA Pharmaceuticals' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow by 63.46% in the coming year, from $0.52 to $0.85 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is -1,605.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is -1,605.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioACADIA Pharmaceuticals has a PEG Ratio of 0.56. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 5.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ACADIA Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressEx-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…Click here now and learn how to prepare. About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD)ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Read More ACAD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACAD Stock News HeadlinesAugust 21, 2024 | insidertrades.comInsider Selling: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) COO Sells 9,534 Shares of StockSeptember 3, 2024 | americanbankingnews.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest Down 7.4% in AugustSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…September 2, 2024 | americanbankingnews.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives $25.56 Consensus Target Price from BrokeragesAugust 30, 2024 | msn.comImplied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock OptionsAugust 30, 2024 | americanbankingnews.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Expected to Earn Q2 2025 Earnings of $0.20 Per ShareAugust 30, 2024 | americanbankingnews.comZacks Research Weighs in on ACADIA Pharmaceuticals Inc.'s Q3 2024 Earnings (NASDAQ:ACAD)August 28, 2024 | businesswire.comAcadia Pharmaceuticals to Participate at Upcoming Investor ConferencesSeptember 7, 2024 | Porter & Company (Ad)The death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.August 26, 2024 | seekingalpha.comAcadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints AgainAugust 21, 2024 | benzinga.comMark Schneyer Implements A Sell Strategy: Offloads $148K In ACADIA Pharmaceuticals StockAugust 21, 2024 | benzinga.comCEO At ACADIA Pharmaceuticals Sells $485K Of StockAugust 16, 2024 | msn.comRyan Reynolds on box office rivalry with Blake Lively: ‘We really root for each other’August 15, 2024 | msn.comRyan Reynolds on his 'complicated' relationship with his dad, how it's changed himAugust 15, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Verrica Pharmaceuticals (VRCA), Celcuity (CELC) and Bluebird Bio (BLUE)August 15, 2024 | msn.comRyan Reynolds Shared the Lesser-Known Parkinson's Symptom That Made His Dad Slip 'Down the Rabbit Hole'August 15, 2024 | msn.comRyan Reynolds and his mom join Parkinson’s education campaignAugust 14, 2024 | finance.yahoo.comShareholders Can Be Confident That ACADIA Pharmaceuticals' (NASDAQ:ACAD) Earnings Are High QualitySee More Headlines Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACAD CUSIPN/A CIK1070494 Webwww.acadia-pharm.com Phone(858) 558-2871Fax858-558-2872Employees510Year FoundedN/APrice Target and Rating Average Stock Price Target$25.56 High Stock Price Target$42.00 Low Stock Price Target$19.00 Potential Upside/Downside+59.1%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E Ratio30.90 P/E Growth0.56Net Income$-61,290,000.00 Net Margins3.43% Pretax Margin5.14% Return on Equity6.89% Return on Assets3.88% Debt Debt-to-Equity RatioN/A Current Ratio2.16 Quick Ratio1.95 Sales & Book Value Annual Sales$890.53 million Price / Sales2.98 Cash FlowN/A Price / Cash FlowN/A Book Value$3.12 per share Price / Book5.15Miscellaneous Outstanding Shares165,221,000Free Float118,463,000Market Cap$2.66 billion OptionableOptionable Beta0.38 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Stephen R. Davis J.D. (Age 63)President, CEO & Director Comp: $1.46MMr. Mark C. Schneyer (Age 49)Executive VP & CFO Comp: $701.03kMr. Brendan P. Teehan (Age 55)Executive VP, COO & Head of Commercial Comp: $724.31kMr. James K. Kihara (Age 43)VP, Chief Accounting Officer & Corporate Controller Dr. Elizabeth H.Z. Thompson Ph.D. (Age 48)Executive VP & Head of Research and Development Mr. Benir RuanoSenior Vice President of Technical Development & OperationsMr. Albert S. KildaniSenior Vice President of Investor Relations & Corporate CommunicationsMs. Jennifer J. Rhodes J.D. (Age 54)Executive VP, Chief Legal Officer & Secretary Ms. Julie FisherSenior Vice President of Marketing & Commercial StrategyMs. Holly ValdiviezSenior VP & Head of SalesMore ExecutivesKey CompetitorsBausch Health CompaniesNYSE:BHCMirati TherapeuticsNASDAQ:MRTXJazz PharmaceuticalsNASDAQ:JAZZIonis PharmaceuticalsNASDAQ:IONSLegend BiotechNASDAQ:LEGNView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 91,834 shares on 9/5/2024Ownership: 0.056%Truist Financial CorpBought 6,887 shares on 8/21/2024Ownership: 0.030%Stonepine Capital Management LLCBought 5,000 shares on 8/21/2024Ownership: 0.003%Stephen DavisSold 31,747 sharesTotal: $485,094.16 ($15.28/share)Brendan TeehanSold 9,534 sharesTotal: $145,679.52 ($15.28/share)View All Insider TransactionsView All Institutional Transactions ACAD Stock Analysis - Frequently Asked Questions How have ACAD shares performed this year? ACADIA Pharmaceuticals' stock was trading at $31.31 at the start of the year. Since then, ACAD stock has decreased by 48.7% and is now trading at $16.07. View the best growth stocks for 2024 here. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its quarterly earnings data on Tuesday, August, 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.02. ACADIA Pharmaceuticals's revenue for the quarter was up 46.4% compared to the same quarter last year. What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO? 8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees. Who are ACADIA Pharmaceuticals' major shareholders? ACADIA Pharmaceuticals' top institutional investors include Millennium Management LLC (1.78%), D. E. Shaw & Co. Inc. (1.78%), Marshall Wace LLP (1.68%) and Fred Alger Management LLC (1.64%). Insiders that own company stock include Bros Advisors Lp Baker, Stephen Davis, Srdjan R Stankovic, Brendan Teehan, Austin D Kim, Mark C Schneyer, James Kihara and Laura Brege. View institutional ownership trends. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA) and Alibaba Group (BABA). This page (NASDAQ:ACAD) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
